Table 1. Clinical and laboratory characteristics of enrolled patients (n = 9843).
| Characteristics | COPD group (n = 229) | Non-COPD group (n = 9614) | P-value |
| Data are presented as means ± SD or n (%). COPD: chronic obstructive pulmonary disease. | |||
| Age, yrs | 65.38 ± 9.13 | 58.27 ± 10.24 | < 0.001 |
| Male | 171 (74.7%) | 7423 (77.2%) | 0.381 |
| Body mass index, kg/m2 | 25.67 ± 3.30 | 25.94 ± 3.15 | 0.188 |
| Coronary heart disease type | |||
| Myocardial infarction | 39 (17.0%) | 1709 (17.8%) | 0.770 |
| Unstable angina | 96 (41.9%) | 4034 (42.0%) | 0.991 |
| Stable coronary artery disease | 94 (41.0%) | 3871 (40.3%) | 0.811 |
| Risk factor | |||
| Current smoking | 137 (59.8%) | 5614 (58.4%) | 0.684 |
| Diabetes mellitus | 67 (29.3%) | 2904 (30.2%) | 0.827 |
| Hypertension | 150 (65.5%) | 6192 (64.4%) | 0.780 |
| Hyperlipidemia | 160 (69.9%) | 6456 (67.2%) | 0.433 |
| Laboratory measurements | |||
| Hemoglobin, g/L | 136.55 ± 16.03 | 141.09 ± 15.84 | < 0.001 |
| Platelet count, × 109/L | 194.73 ± 50.27 | 203.60 ± 54.98 | 0.016 |
| Estimated glomerular filtration rate, mL/min per 1.73 m2 | 84.09 ± 16.13 | 91.35 ± 15.07 | < 0.001 |
| Low-density lipoprotein cholesterol, mmol/L | 2.48 ± 0.86 | 2.51 ± 0.92 | 0.667 |
| Left ventricular ejection fraction, % | 61.65 ± 7.31 | 62.77 ± 7.32 | 0.025 |
| Medications | |||
| Aspirin | 223 (97.4%) | 9491 (98.7%) | 0.127 |
| P2Y12 receptor antagonist | 228 (99.6%) | 9611 (99.9%) | 0.177 |
| Angiotensin-converting enzyme inhibitors/Angiotensin II
receptor blockers |
19 (8.3%) | 740 (7.7%) | 0.707 |
| Beta-blocker | 201 (87.8%) | 8667 (90.1%) | 0.220 |
| Calcium channel blocker | 128 (55.9%) | 4656 (48.4%) | 0.027 |
| Nitrates | 225 (98.3%) | 9398 (97.8%) | 0.821 |
| Statin | 224 (97.8%) | 9218 (95.9%) | 0.175 |
| Proton pump inhibitor | 57 (24.9%) | 1917 (19.9%) | 0.066 |